R&D Systems™ Recombinant Human B7-1/CD80 His-tag Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Manufacturer: R&D Systems™ 9050B1100
DescriptionMeasured by its binding ability in a functional ELISA. When Recombinant Human B7-1/CD80 is immobilized at 1 μg/mL (100 μL/well), the concentration of Recombinant Human CTLA-4 Fc Chimera (Catalog # 7268-CT ) that produces 50% of the optimal binding response is approximately 0.05-0.3 μg/mL.
|Lyophilized from a 0.2 µm filtered solution in PBS.|
|M.W. (Observed): 45-58 kDa, reducing conditions; M.W. (theoretical): 25 kDa|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.|
|Activation B7-1 antigen, B7, B71, BB1, CD28LG1, CD28LGB7-1 antigen), CD80, CD80 antigen, CD80 molecule, costimulatory factor CD80, costimulatory molecule variant IgV-CD80, CTLA-4 counter-receptor B7.1, T-lymphocyte activation antigen CD80|
|Human embryonic kidney cell, HEK293-derived Val35-Asn242, with a C-terminal 6-His tag|
|>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.|
|Human embryonic kidney cell, HEK293-derived human B7-1/CD80 protein Val35-Asn242, with a C-terminal 6-His tag|
|<0.10 EU / 1 µg of the protein by the LAL method.|
|Measured by its binding ability in a functional ELISA. When Recombinant Human B7-1/CD80 is immobilized at 1μg/mL (100μL/well), the concentration of Recombinant Human CTLA-4 Fc Chimera that produces 50% of the optimal binding response is approximately 0.05-0.3μg/mL.|
|Reconstitute at 500 µg/mL in PBS.|